医学
达沙替尼
索拉非尼
不利影响
帕唑帕尼
酪氨酸激酶抑制剂
伊马替尼
内科学
酪氨酸激酶
药理学
克里唑蒂尼
食品药品监督管理局
肿瘤科
癌症
舒尼替尼
肝细胞癌
髓系白血病
恶性胸腔积液
受体
胸腔积液
作者
Hari K. Narayan,Karyn Sheline,Victor Wong,D.Y.S. Kuo,Sun Choo,Janet Yoon,Kasey J. Leger,Shelby Kutty,Michael Fradley,Adriana H. Tremoulet,Bonnie Ky,Saro H. Armenian,Avirup Guha
摘要
We sought to examine cardiovascular toxicities associated with tyrosine kinase inhibitors in pediatrics. We examined 1624 pediatric adverse events with imatinib, dasatinib, sorafenib, pazopanib, crizotinib, and ruxolitinib reported to the Food and Drug Administration between January 1, 2015, and August 14, 2020. There were 102 cardiovascular event reports. Hypertension was the most commonly reported cardiovascular event and was most frequently associated with sorafenib and pazopanib. The presence of infection increased the reporting odds of cardiovascular events overall and specifically cardiac arrest, heart failure, and hypertension. These data provide early insight into cardiovascular toxicities with tyrosine kinase inhibitor use in pediatrics.
科研通智能强力驱动
Strongly Powered by AbleSci AI